174 related articles for article (PubMed ID: 33705973)
1. Mutation and Expression of Gene YY1 in Pancreatic Neuroendocrine Tumors and Its Clinical Significance.
Song YL; Xu J; Zhao DC; Zhang TP; Jin KZ; Zhu LM; Yu S; Chen YJ
Endocr Pract; 2021 Sep; 27(9):874-880. PubMed ID: 33705973
[TBL] [Abstract][Full Text] [Related]
2. Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1.
Cao Y; Gao Z; Li L; Jiang X; Shan A; Cai J; Peng Y; Li Y; Jiang X; Huang X; Wang J; Wei Q; Qin G; Zhao J; Jin X; Liu L; Li Y; Wang W; Wang J; Ning G
Nat Commun; 2013; 4():2810. PubMed ID: 24326773
[TBL] [Abstract][Full Text] [Related]
3. Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas.
Lichtenauer UD; Di Dalmazi G; Slater EP; Wieland T; Kuebart A; Schmittfull A; Schwarzmayr T; Diener S; Wiese D; Thasler WE; Reincke M; Meitinger T; Schott M; Fassnacht M; Bartsch DK; Strom TM; Beuschlein F
J Clin Endocrinol Metab; 2015 May; 100(5):E776-82. PubMed ID: 25763608
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
[TBL] [Abstract][Full Text] [Related]
5. [Expression of YY 1 protein in human insulinoma and its clinical implication].
Li WX; Huang YE; Shi XX; Lin PX; Zhou ZN; Zhang YZ; Shen H
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Mar; 36(3):361-4. PubMed ID: 27063163
[TBL] [Abstract][Full Text] [Related]
6. T372R Mutation Status in Yin Yang 1 Gene in Insulinoma Patients.
Irshad K; Jyotsna VP; Agarwal S; Chosdol K; Pal S; Deepak RK
Horm Metab Res; 2017 Jun; 49(6):452-456. PubMed ID: 28472826
[TBL] [Abstract][Full Text] [Related]
7. Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas.
Cromer MK; Choi M; Nelson-Williams C; Fonseca AL; Kunstman JW; Korah RM; Overton JD; Mane S; Kenney B; Malchoff CD; Stalberg P; Akerström G; Westin G; Hellman P; Carling T; Björklund P; Lifton RP
Proc Natl Acad Sci U S A; 2015 Mar; 112(13):4062-7. PubMed ID: 25787250
[TBL] [Abstract][Full Text] [Related]
8. α-Internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness.
Liu B; Tang LH; Liu Z; Mei M; Yu R; Dhall D; Qiao XW; Zhang TP; Zhao YP; Liu TH; Xiao Y; Chen J; Xiang HD; Wu HY; Lu CM; Lv B; Zhou YR; Zhang Y; Deng D; Chen YJ
J Clin Endocrinol Metab; 2014 May; 99(5):E786-95. PubMed ID: 24483152
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine cancer: Insulinomas-recurrent mutations identified in YY1.
Greenhill C
Nat Rev Endocrinol; 2014 Mar; 10(3):127. PubMed ID: 24366121
[No Abstract] [Full Text] [Related]
11. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
[TBL] [Abstract][Full Text] [Related]
13. Frequency and consequence of the recurrent
Parekh VI; Modali SD; Welch J; Simonds WF; Weinstein LS; Kebebew E; Agarwal SK
Endocr Relat Cancer; 2018 May; 25(5):L31-L35. PubMed ID: 29467239
[No Abstract] [Full Text] [Related]
14. Expression of transcription factors in MEN1-associated pancreatic neuroendocrine tumors.
Takeda Y; Fujita Y; Sakai K; Abe T; Nakamura T; Yanagimachi T; Sakagami H; Honjo J; Abiko A; Makino Y; Haneda M
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 28924486
[TBL] [Abstract][Full Text] [Related]
15. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.
Hong X; Qiao S; Li F; Wang W; Jiang R; Wu H; Chen H; Liu L; Peng J; Wang J; Jia C; Liang X; Dai H; Jiang J; Zhang T; Liao Q; Dai M; Cong L; Han X; Guo D; Liang Z; Li D; Zheng Z; Ye C; Li S; Zhao Y; Wu K; Wu W
Gut; 2020 May; 69(5):877-887. PubMed ID: 31462556
[TBL] [Abstract][Full Text] [Related]
16. Synchronous Insulinoma and Glucagonoma: A Review of the Literature.
Damaskos C; Dimitroulis D; Garmpi A; Antoniou EA; Kouraklis G; Psilopatis I; Mavri M; Diamantis E; Marinos G; Kyriakos G; Farmaki P; Patsouras A; Kontzoglou K; Garmpis N
In Vivo; 2023; 37(6):2402-2408. PubMed ID: 37905620
[TBL] [Abstract][Full Text] [Related]
17. Proinsulin Expressing Neuroendocrine Tumors of the Pancreas: An Underrecognized Entity.
Celli R; Tang LH; Cai G; Freedman-Weiss M; Colunga M; Salem RR; Majumdar S; Jain D
Pancreas; 2019 Jan; 48(1):55-59. PubMed ID: 30451800
[TBL] [Abstract][Full Text] [Related]
18. Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study.
Zhu LM; Tang L; Qiao XW; Wolin E; Nissen NN; Dhall D; Chen J; Shen L; Chi Y; Yuan YZ; Ben QW; Lv B; Zhou YR; Bai CM; Chen J; Song YL; Song TT; Lu CM; Yu R; Chen YJ
Medicine (Baltimore); 2016 Feb; 95(7):e2836. PubMed ID: 26886644
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.
Modali SD; Parekh VI; Kebebew E; Agarwal SK
Mol Endocrinol; 2015 Feb; 29(2):224-37. PubMed ID: 25565142
[TBL] [Abstract][Full Text] [Related]
20. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
Liu IH; Ford JM; Kunz PL
Cancer Treat Rev; 2016 Mar; 44():1-9. PubMed ID: 26924193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
